RESUMO
Nicergoline (NE)--a cerebral vasodilator with nicotinic acid esterified in its molecule--and Antagonic-Stress (AS) composition--a neurometabolic nootropic, also containing nicotinic acid but with fast and prolonged release--were evaluated in senile dementia of Alzheimer's type (SDAT), mild to moderate intensity (DSM-IV Options Book, 1991 and ICD-10, 1990 criteria). A double-blind, randomized, comparative, and parallel clinical trial was performed on 62 old people divided into 2 groups and exclusively treated with NE or AS. Psychogeriatric evaluations (Sandoz Clinical Assessment-Geriatric scale, Self-Assessment Scale-Geriatric and their subscales) and psychometric tests (digit symbol of WAIS, Wechsler Memory Scale, and Wechsler Adult Intelligence Scale-WAIS) were made before and after 3 months of treatment. Prolonged and large dose treatments with NE and AS significantly decreased the psychogeriatric scores, diminished the deterioration index, and improved cognitive performances (ANOVA). Therapeutical effects of AS were significantly higher than those of NE (ANCOVA). The better actions of AS in senile dementia and for improving cognitive function and behavior are discussed in connection with its multiple neurometabolic composition, the synergism of components, the antiischemic action of its antioxidants, its anti-free radical complementary action (deceleration of the aging rate, brain and erythrocyte lipofuscinolysis, complex antioxidative and scavenger formula), the multivitamin and multimineral supplementation and, finally, with the superiority of multitherapy vs. monotherapy.
Assuntos
Demência/tratamento farmacológico , Meclofenoxate/uso terapêutico , Niacina/uso terapêutico , Nicergolina/uso terapêutico , Ácido Orótico/uso terapêutico , Psicotrópicos/uso terapêutico , Vasodilatadores/farmacologia , Idoso , Envelhecimento/efeitos dos fármacos , Método Duplo-Cego , Combinação de Medicamentos , Feminino , Avaliação Geriátrica , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
A double blind, comparative, parallel and randomized clinical trial was used for evaluation of two nootropics with anti-aging actions: Meclofenoxate (MF) and Antagonic-Stress (AS). Sixty-three old persons divided into 2 groups (average age: 68.6 and 70.8 years, respectively) with senile dementia of Alzheimer type (SDAT), of mild to moderate intensity (criteria of DSM-III-R, APA, 1987; and ICD-10, WHO, 1990) were treated with one of these nootropica. Baseline and final psychogeriatric symptomatology after three months of treatments were multiply assessed: psychogeriatric by Sandoz Clinical Assessment-Geriatric scale, Self-Assessment Scale-Geriatric and their subscales; psychometric by Wechsler Memory Scale and Wechsler Adult Intelligence Scale. Prolonged treatments with MF and AS significantly decreased the psychogeriatric scores in scales and subscales, improved the cognitive performance (attention, concentration, memory, performance IQ, full IQ) and diminshed the deterioration index (ANOVA). Therapeutical effects of AS (a neurometabolic complex containing MF) were significantly superior against MF alone (ANCOVA). MF and AS actions are discussed in connection with the brain cholinergic system, lipid peroxidation and free radical scavengers, deceleration of the aging rate, brain and erythrocyte lipofuscinolysis, multiple anti-oxidant formula, multivitamin and multimineral supplementation and with the superiority of multitherapy versus monotherapy in senile dementia and for improving the IQ and the maladaptative behavior.
RESUMO
The submaximal test of triangular type was used for studying the adaptability to exercise, on an ergometric bicycle. It was performed, starting from O W, with progressive increasing load of 10 W/min until the maximum optimum heart rate (fho) was reached. The heart rate, arterial blood pressure, electrocardiogram, CO2 output and O2 consumption. Computed O2 consumption (VO2 max, ml/kg/min, Astrand) were determined, also taking into account the subjective sensation linked to exercise, measured on a modified Borg scale. The adaptability capacity to exercise was expressed by the adaptability coefficient (AC), according to the formula: AC = W'/2 + (W'-f'). 20 hyperthyroid patients, without cardiothyreosis were examined, both before the uptake of propranolol and after, at a certain interval of time. A decrease of the exercise capacity before the treatment and its increase after it, was noticed in the hyperthyroid patients.
Assuntos
Hipertireoidismo/fisiopatologia , Esforço Físico/efeitos dos fármacos , Receptores Adrenérgicos beta/efeitos dos fármacos , Adaptação Fisiológica/efeitos dos fármacos , Adulto , Teste de Esforço , Feminino , Humanos , Hipertireoidismo/tratamento farmacológico , Masculino , Propranolol/uso terapêuticoRESUMO
The submaximal triangular-type test was used for studying the adaptive capacity, on an ergometric bicycle. It was performed continuously, starting from O W, with a load increment of 10 watts/min up to optimal maximum heart rate (fmo). The heart rate, arterial blood pressure, electrocardiogram, CO2 output and O2 consumption computed maximal O2 consumption (VO2 max, ml/kg/min) (Astrand) were predicted, also taking into consideration the subjective sensations linked to effort, measured on a modified Borg scale. The capacity to effort was expressed by the "adaptability coefficient" (AC) according to formula: AC = W' divided by 2 + (W' --f). 40 hyperthyroid patients, compared to a lot of normal thyroid subjects were examined, both at the beginning and after the treatment at certain intervals of time. A decrease of the effort capacity before the treatment and its increase after was noticed in hyperthyroid patients.